留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

多发性骨髓瘤的影像学评估

赵多多 庄俊玲

赵多多, 庄俊玲. 多发性骨髓瘤的影像学评估[J]. 协和医学杂志, 2020, 11(3): 305-308. doi: 10.3969/j.issn.1674-9081.20190213
引用本文: 赵多多, 庄俊玲. 多发性骨髓瘤的影像学评估[J]. 协和医学杂志, 2020, 11(3): 305-308. doi: 10.3969/j.issn.1674-9081.20190213
Duo-duo ZHAO, Jun-ling ZHUANG. Imaging Techniques in the Assessment of Multiple Myeloma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 305-308. doi: 10.3969/j.issn.1674-9081.20190213
Citation: Duo-duo ZHAO, Jun-ling ZHUANG. Imaging Techniques in the Assessment of Multiple Myeloma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 305-308. doi: 10.3969/j.issn.1674-9081.20190213

多发性骨髓瘤的影像学评估

doi: 10.3969/j.issn.1674-9081.20190213
基金项目: 

北京市自然科学基金 7192175

详细信息
    通讯作者:

    庄俊玲 电话:010-69155027,E-mail:zhuangjunling@pumch.cn

  • 中图分类号: R445.1;R551.3

Imaging Techniques in the Assessment of Multiple Myeloma

More Information
  • 摘要: 多发性骨髓瘤具有独特的骨病表现,由于破骨细胞激活和成骨细胞功能抑制导致溶骨性破坏和严重骨质疏松。骨病严重程度对患者生活质量和生存均有负面影响。普通X线检出骨病的灵敏度很低,CT的灵敏度虽明显提高,但难以检出骨外病变。功能性影像方法(主要包括磁共振弥散加权成像和正电子发射断层显像/计算机体层成像)不仅能发现早期溶骨病灶,且在评估全身肿瘤负荷和缓解后微小残留病变方面更有优势。本文将对这些方面的进展进行综述。
    利益冲突  无
  • [1] 张之南,单渊东,李蓉生,等. 协和血液病学[M]. 北京:中国协和医科大学出版社,2004:497.
    [2] Roodman GD. Pathogenesis of myeloma bone disease[J]. Blood Cells Mol Dis, 2004, 32:290-292. doi:  10.1016/j.bcmd.2004.01.001
    [3] Dimopoulos M, Terpos E, Comenzo RL, et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma[J]. Leukemia, 2009, 23:1545-1556. doi:  10.1038/leu.2009.89
    [4] Derlin T, Bannas P. Imaging of multiple myeloma:current concepts[J]. World J Orthop, 2014, 5:272-282. doi:  10.5312/wjo.v5.i3.272
    [5] Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease:a systematic review[J]. Br J Haematol, 2013, 162:50-61. doi:  10.1111/bjh.12346
    [6] Horger M, Claussen CD, Bross-Bach U, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma:an alternative to conventional radiography[J]. Eur J Radiol, 2005, 54:289-297. doi:  10.1016/j.ejrad.2004.04.015
    [7] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15:538-548. doi:  10.1016/S1470-2045(14)70442-5
    [8] Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma[J]. AJR Am J Roentgenol, 2008, 190:1097-1104. doi:  10.2214/AJR.07.2635
    [9] Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma:a consensus statement[J]. J Clin Oncol, 2015, 33:657-664. doi:  10.1200/JCO.2014.57.9961
    [10] Walker R, Barlogie B, Haessler J, et al. Magnetic res-onance imaging in multiple myeloma:diagnostic and clinical implications[J]. J Clin Oncol, 2007, 25:1121-1128. doi:  10.1200/JCO.2006.08.5803
    [11] Hillengass J, Bäuerle T, Bartl R, et al. Diffusion-weighted imaging for non- invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease:a comparative study with histology[J]. Br J Haematol, 2011, 153:721-728. doi:  10.1111/j.1365-2141.2011.08658.x
    [12] Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma[J]. Leukemia, 2019, 33:1713-1722. doi:  10.1038/s41375-018-0329-0
    [13] Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders:a consensus statement by the International Myeloma Working Group[J]. Lancet Oncol, 2017, 18:206-217. doi:  10.1016/S1470-2045(17)30189-4
    [14] Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J]. Blood, 2013, 121:1819-1823. doi:  10.1182/blood-2012-08-451690
    [15] Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation[J]. Blood, 2011, 118:5989-5995. doi:  10.1182/blood-2011-06-361386
    [16] Zamagni E, Nanni C, Mancuso K, et al. PET/CT Improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma[J]. Clin Cancer Res, 2015, 21:4384-4390. doi:  10.1158/1078-0432.CCR-15-0396
    [17] Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia, 2014, 28:391. doi:  10.1038/leu.2013.217
    [18] Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123:3073-3079. doi:  10.1182/blood-2014-01-550020
    [19] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised, open-label, phase 3 study[J]. Lancet,2019,394:29-38. doi:  10.1016/S0140-6736(19)31240-1
    [20] 金媛媛,庄俊玲.新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J].协和医学杂志,2018,9:219-223. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201803007
    [21] Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016, 17:e328-e346. doi:  10.1016/S1470-2045(16)30206-6
    [22] Rasche L, Angtuaco E, MC Donald JE, et al. Low expression of Hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J]. Blood, 2017, 130:30-34. doi:  10.1182/blood-2017-03-774422
    [23] Lapa C, Garcia-Velloso MJ, Lückerath K, et al. 11C-Methionine-PET in multiple myeloma:a combined study from two different institutions[J]. Theranostics, 2017, 7:2956-2964. doi:  10.7150/thno.20491
    [24] Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma[J]. EMBO Mol Med, 2015, 7:477-487. doi:  10.15252/emmm.201404698
  • 加载中
计量
  • 文章访问数:  603
  • HTML全文浏览量:  55
  • PDF下载量:  97
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-10-06
  • 刊出日期:  2020-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!